Critics argue that the importation of unapproved medicines would help save consumers money. What proponents of importation often miss is the critical issue of safety and how this would impact access to new, innovative treatments.
Medicare Part B provides coverage to 44.9 million seniors and 8.9 million people with disabilities for medically necessary services, therapies and supplies used to diagnose and treat their health conditions. On March 8, 2016, the Centers for Medicare & Medicaid Services (CMS) released a controversial proposed rule, the Medicare Part B Drug Payment Model, designed to reduce the cost of Medicare Part B by testing alternative payment models that will limit patient access to life-saving medicines.
Since 2000, biopharmaceutical companies have brought more than 500 new medicines to patients in the U.S. As a result, we have successfully improved the quality and length of life for Americans confronting the most costly and challenging diseases (cancer, diabetes, etc.).
Biologics are complex medicines manufactured using living cells and tissues. America’s biopharmaceutical research companies are using biological processes testing 907 medicines and vaccines targeting more than 100 diseases. In order to realize the full potential of biologics, it is essential that the U.S. maintain policy and regulatory environments that help foster the discovery and development processes.
Medicare Part D is the government program that provides seniors and people with disabilities with access to affordable prescription drug coverage. Through market-based competition, Part D allows beneficiaries to choose from a range of private plans that best meet their needs. Today, 90% of Medicare beneficiaries have comprehensive prescription drug coverage, and a majority receives their coverage through Part D.